Literature DB >> 29636327

Should all patients with Hodgkin lymphoma who relapse after autologous SCT be considered for allogeneic SCT?

Karl S Peggs1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29636327      PMCID： PMC5894255          DOI： 10.1182/bloodadvances.2017011122

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  19 in total

1.  Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation.

Authors:  Karl S Peggs; Ann Hunter; Rajesh Chopra; Anne Parker; Premini Mahendra; Donald Milligan; Charles Craddock; Ruth Pettengell; Ahmet Dogan; Kirsty J Thomson; Emma C Morris; Geoff Hale; Herman Waldmann; Anthony H Goldstone; David C Linch; Stephen Mackinnon
Journal:  Lancet       Date:  2005 Jun 4-10       Impact factor: 79.321

2.  Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantation.

Authors:  C Martínez; C Canals; B Sarina; E P Alessandrino; D Karakasis; A Pulsoni; S Sica; M Trneny; J A Snowden; E Kanfer; N Milpied; A Bosi; S Guidi; C A de Souza; R Willemze; R Arranz; L Jebavy; A Hellmann; D Sibon; R Oneto; J J Luan; P Dreger; L Castagna; A Sureda
Journal:  Ann Oncol       Date:  2013-05-26       Impact factor: 32.976

3.  Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: guidelines from the American Society for Blood and Marrow Transplantation.

Authors:  Miguel-Angel Perales; Izaskun Ceberio; Philippe Armand; Linda J Burns; Robert Chen; Peter D Cole; Andrew M Evens; Ginna G Laport; Craig H Moskowitz; Uday Popat; Nishitha M Reddy; Thomas C Shea; Julie M Vose; Jeffrey Schriber; Bipin N Savani; Paul A Carpenter
Journal:  Biol Blood Marrow Transplant       Date:  2015-03-12       Impact factor: 5.742

4.  Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.

Authors:  Robert Chen; Pier Luigi Zinzani; Michelle A Fanale; Philippe Armand; Nathalie A Johnson; Pauline Brice; John Radford; Vincent Ribrag; Daniel Molin; Theodoros P Vassilakopoulos; Akihiro Tomita; Bastian von Tresckow; Margaret A Shipp; Yinghua Zhang; Alejandro D Ricart; Arun Balakumaran; Craig H Moskowitz
Journal:  J Clin Oncol       Date:  2017-04-25       Impact factor: 44.544

5.  Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation as Alternative to Matched Sibling or Unrelated Donor Transplantation for Hodgkin Lymphoma: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation.

Authors:  Carmen Martínez; Jorge Gayoso; Carmen Canals; Hervé Finel; Karl Peggs; Alida Dominietto; Luca Castagna; Boris Afanasyev; Stephen Robinson; Didier Blaise; Paolo Corradini; Maija Itälä-Remes; Arancha Bermúdez; Edouard Forcade; Domenico Russo; Michael Potter; Grant McQuaker; Ibrahim Yakoub-Agha; Christof Scheid; Adrian Bloor; Silvia Montoto; Peter Dreger; Anna Sureda
Journal:  J Clin Oncol       Date:  2017-08-28       Impact factor: 44.544

6.  Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma.

Authors:  Charles Herbaux; Jordan Gauthier; Pauline Brice; Elodie Drumez; Loic Ysebaert; Hélène Doyen; Luc Fornecker; Krimo Bouabdallah; Guillaume Manson; Hervé Ghesquières; Reza Tabrizi; Eric Hermet; Julien Lazarovici; Anne Thiebaut-Bertrand; Adrien Chauchet; Hélène Demarquette; Eileen Boyle; Roch Houot; Ibrahim Yakoub-Agha; Franck Morschhauser
Journal:  Blood       Date:  2017-03-07       Impact factor: 22.113

7.  Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes.

Authors:  Karl S Peggs; Anna Sureda; Wendi Qian; Dolores Caballero; Ann Hunter; Alvaro Urbano-Ispizua; James Cavet; Josep M Ribera; Anne Parker; Miguel Canales; Premini Mahendra; Javier Garcia-Conde; Donald Milligan; Guillermo Sanz; Kirsty Thomson; Reyes Arranz; Anthony H Goldstone; Ivan Alvarez; David C Linch; Jorge Sierra; Stephen Mackinnon
Journal:  Br J Haematol       Date:  2007-10       Impact factor: 6.998

8.  Brentuximab vedotin is associated with improved progression-free survival after allogeneic transplantation for Hodgkin lymphoma.

Authors:  Robert Chen; Joycelynne M Palmer; Ni-Chun Tsai; Sandra H Thomas; Tanya Siddiqi; Leslie Popplewell; Len Farol; Auayporn Nademanee; Stephen J Forman
Journal:  Biol Blood Marrow Transplant       Date:  2014-07-05       Impact factor: 5.742

9.  Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies.

Authors:  Nancy L Bartlett; Robert Chen; Michelle A Fanale; Pauline Brice; Ajay Gopal; Scott E Smith; Ranjana Advani; Jeffrey V Matous; Radhakrishnan Ramchandren; Joseph D Rosenblatt; Dirk Huebner; Pamela Levine; Laurie Grove; Andres Forero-Torres
Journal:  J Hematol Oncol       Date:  2014-03-19       Impact factor: 17.388

10.  Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.

Authors:  Anas Younes; Armando Santoro; Margaret Shipp; Pier Luigi Zinzani; John M Timmerman; Stephen Ansell; Philippe Armand; Michelle Fanale; Voravit Ratanatharathorn; John Kuruvilla; Jonathon B Cohen; Graham Collins; Kerry J Savage; Marek Trneny; Kazunobu Kato; Benedetto Farsaci; Susan M Parker; Scott Rodig; Margaretha G M Roemer; Azra H Ligon; Andreas Engert
Journal:  Lancet Oncol       Date:  2016-07-20       Impact factor: 41.316
View more
  5 in total

1.  Allogeneic transplantation using TLI-ATG conditioning for Hodgkin lymphoma after failure of autologous transplantation.

Authors:  Michael A Spinner; Ranjana H Advani; Richard T Hoppe; Robert Lowsky; Lori S Muffly
Journal:  Blood Adv       Date:  2018-07-10

2.  Allogeneic stem cell transplantation improves survival in relapsed Hodgkin lymphoma patients achieving complete remission after salvage treatment.

Authors:  María Marta Rivas; Mariano Berro; María Virginia Prates; Sebastián Yantorno; Lorena Fiad; Jorge Alberto Arbelbide; Ana Lisa Basquiera; Gonzalo Ariel Ferini; Juan José García; Pablo Andrés García; Leandro Riera; Gustavo Jarchum; Alfredo Baso; Juan Real; Martín Castro; Gregorio Jaimovich; Juliana Martinez Rolón; Cecilia Foncuberta; Silvia Saba; Gustavo Kusminsky
Journal:  Bone Marrow Transplant       Date:  2019-08-21       Impact factor: 5.483

3.  Allo-HSCT in transplant-naïve patients with Hodgkin lymphoma: a single-arm, multicenter study.

Authors:  Emma Das-Gupta; Kirsty J Thomson; Adrian J C Bloor; Andrew D Clark; Stephen Mackinnon; Irfan Kayani; Laura Clifton-Hadley; Pip Patrick; Nadjet El-Mehidi; Anthony Lawrie; Amy A Kirkwood; Nigel H Russell; David C Linch; Karl S Peggs
Journal:  Blood Adv       Date:  2019-12-23

Review 4.  Reappraising the Role of Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed and Refractory Hodgkin's Lymphoma: Recent Advances and Outcomes.

Authors:  Taha Al-Juhaishi; Azra Borogovac; Sami Ibrahimi; Matthew Wieduwilt; Sairah Ahmed
Journal:  J Pers Med       Date:  2022-01-18

Review 5.  Optimizing outcomes in relapsed/refractory Hodgkin lymphoma: a review of current and forthcoming therapeutic strategies.

Authors:  Theodoros P Vassilakopoulos; John V Asimakopoulos; Kostas Konstantopoulos; Maria K Angelopoulou
Journal:  Ther Adv Hematol       Date:  2020-02-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.